CG0070 for Bladder Cancer
Time: 1:00 pm
day: Day One
Details:
- The data on CG0070 for NMIBC as a single agent will be reviewed
- The data on CG0070 in combination with pembrolizumab for NMIBC will be reviewed
- The data on CG0070 plus nivolumab for MIBC will be reviewed
